Indication
Stage IV B-Cell Non-Hodgkin Lymphoma
3 clinical trials
7 products
3 drugs
Clinical trial
A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Drug
cyclophosphamideProduct
DoxorubicinProduct
EtoposideProduct
NivolumabProduct
PrednisoneDrug
VarlilumabDrug
VincristineClinical trial
Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's LymphomasStatus: Recruiting, Estimated PCD: 2024-12-31
Product
IbrutinibProduct
ObinutuzumabClinical trial
Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Product
Orbital Radiation